2015 American Transplant Congress
Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…2015 American Transplant Congress
The Effects of Donor Specific Anti- Human Leukocyte Antigen Antibodies Late After Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of anti-HLA antibodies following heart transplantation has been associated with poor outcomes, including lower survival and increased risk for the development of…2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…2015 American Transplant Congress
Can Gene-Expression Profiling Score Help Explain the Adverse Clinical Outcomes Seen in Gender-Mismatched Heart Transplants?
Background: Gene-expression profiling (GEP) testing, in conjunction with clinical assessment, is an established laboratory test intended to aid in the identification of acute cellular rejection…2015 American Transplant Congress
Human CMV-Specific CD8 T Cells Exhibit Distinct Phenotypes and Distribution Patterns in Tissues and Circulation
IntroductionCMV persists and is controlled by T cells in multiple tissues; however, study of CMV responses has largely been limited to blood containing only 2-3%…2015 American Transplant Congress
CMV IgG Provides Similar Anti-CMV Efficacy as Valganciclovir in High-Risk Organ Transplant Recipients, With Reduced Costs
Abdominal organ transplants at high risk for CMV infection (D+/R-) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration. Administration…2015 American Transplant Congress
Cytomegalovirus and BK Infections in Sensitized Kidney Transplant Recipients
Department of Medicine, University of Wisconsin School of Medicine and Pubic Health, Madison.
Background:There is little information on the incidence, risk factors and outcomes associated with cytomegalovirus (CMV) and BK infections in sensitized patientsMethods:We examined 254 kidney transplant…2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…2015 American Transplant Congress
Recurrent Cytomegalovirus Infection After Solid Organ Transplant
University Health Network, Toronto, Canada.
Background:Cytomegalovirus is a common opportunistic infection after transplant. Relapse may occur after treatment of the initial episode of viremia or disease and secondary prophylaxis is…
American Transplant Congress abstracts